

LISI AGAIN ACHIEVES GROWTH TARGETS IN 2016

- Growth in performance indicators in absolute terms:
 - Sale: € 1.57 billion, up € 113 million (+7.8%), reflecting the incorporation of LISI MEDICAL Remmele (€ 45 million for 7 months) in particular;
 - Organic growth: +4.6%, driven by the three divisions;
 - EBIT up € 11 million (+7.5%), with operating margin in line with the strategic target of 10.0%;
 - Positive Free Cash-Flow*, up almost € 34 million at € 74 million.
- Financial strength maintained:
 - Net debt / EBITDA ratio maintained below than 1, despite substantial capital expenditure programs (€ 120 million) and financial investments (€ 94 million) in 2016.
- Net earnings per share up: +30.0%;
- Proposed dividend: € 0.45 per share;
- 2017 targets: to continue and consolidate performance over the long-term.

February 21, 2017 - The LISI Board of Directors has met under the chairmanship of Mr. Gilles KOHLER and assessed the final financial statements for the period ended December 31, 2016. These will be submitted for approval to the Annual General Meeting of Shareholders on April 25, 2017.

<i>12 months ended 31 December</i>		<i>2016</i>	<i>2015</i>	<i>Variance</i>
Main items of income statement				
Sales	€M	1,571.1	1,458.1	7.8%
EBITDA	€M	237.1	204.1	16.2%
EBITDA margin	%	15.1	14.0	+1.1 pt
EBIT	€M	157.5	146.5	7.5%
Operating margin	%	10.0	10.0	-
Earnings attributable to equity holders of the company	€M	107.0	81.8	30.9%
Net earnings per share	€	2.02	1.55	30.3%
Cash flow				
Cash flow	€M	195.8	154.2	€ 41.6 M
Net capital expenditure	€M	-119.6	-111.5	€ 8.1 M
Free Cash Flow*	€M	73.5	39.6	€ 33.9 M
Debt and equity				
Net debt	€M	218.2	156.6	€ 61.6 M
Ratio of net debt to shareholders' equity		25.2%	19.7%	+5.5 pts

* Free Cash Flow: cash flow less net industrial investments and variances in working capital requirements

With this in mind the LISI Group is aiming in 2017 a growth in its operating results and a Free Cash Flow that continues to be positive.

The full press release and the Group's financial information are available on the website: www.lisi-group.com.

Contact

Emmanuel Viellard

Tel: 03 84 57 00 77

E-mail: emmanuel.viellard@lisi-group.com

Website: www.lisi-group.com

The next publications will appear after the end of trading on Paris Euronext.

Shareholders' Annual General Meeting: April 25, 2017

Q1 2017 financial information: April 26, 2017

Results for 1st half 2017: July 26, 2017

Q3 2017 financial information: October 25, 2017

The LISI share is listed on Euronext Paris, Section A and is on the CAC® AERO & DEF., CAC® All Shares, CAC® Industrials indices, under ISIN code: FR 0000050353. LISI is a world leader in fasteners and assembly components for the Aerospace, Automotive and medical implants sectors.

Reuters Code: GFII.PA

Bloomberg Code: FII FP